Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 4, 2010, Pages 543-547

  Kalaycio, Matt E ^a   Kukreja, Manisha ^b   Woolfrey, Ann E ^c   Szer, Jeffrey ^d   Cortes, Jorge ^e   Maziarz, Richard T ^f   Bolwell, Brian J ^a   Buser, Andreas ^g   Copelan, Edward ^a   Gale, Robert Peter ^h   Gupta, Vikas ⁱ   Maharaj, Dipnarine ^j   Marks, David I ^k   Pavletic, Steven Z ^l   Horowitz, Mary M ^b   Arora, Mukta ^m  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g Blutspendezentrum   (Switzerland)

^h CELGENE CORPORATION   (United States)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j South Florida Bone Marrow Stem Cell Transplant Institute   (United States)

^k BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

^l NATIONAL CANCER INSTITUTE   (United States)

^m UNIVERSITY OF MINNESOTA MEDICAL CENTER   (United States)

more..

Author keywords

Allogeneic stem cell transplantation; Prolymphocytic leukemia

Indexed keywords

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROLYMPHOCYTIC LEUKEMIA; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA, PROLYMPHOCYTIC; MIDDLE AGED; PROCEDURES;

ADULT; AGED; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, PROLYMPHOCYTIC; MALE; MIDDLE AGED; PROGNOSIS; TRANSPLANTATION CONDITIONING;

EID: 77949271439     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.11.021     Document Type: Article

References (20)

1. Absi A., Hsi E., and Kalaycio M. Prolymphocytic leukemia. Curr Treat Options Oncol 6 (2005) 197-208
2. Matutes E., Brito-Babapulle V., Swansbury J., et al. Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78 (1991) 3269-3274
3. Durig J., Bug S., Klein-Hitpass L., et al. Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14)(q11q32). Leukemia 21 (2007) 2153-2163
4. Pekarsky Y., Hallas C., and Croce C.M. Molecular basis of mature T-cell leukemia. JAMA 286 (2001) 2308-2314
5. Pekarsky Y., Hallas C., and Croce C.M. The role of TCL1 in human T-cell leukemia. Oncogene 20 (2001) 5638-5643
6. Matutes E., Owusu-Ankomah K., Morilla R., et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia 8 (1994) 1640-1645
7. Lorand-Metze I., Oliveira G.B., and Aranha F.J. Treatment of prolymphocytic leukemia with cladribine. Ann Hematol 76 (1998) 85-86
8. Mercieca J., Matutes E., Dearden C., MacLennan K., and Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 12 (1994) 2588-2593
9. Kantarjian H.M., Redman J.R., and Keating M.J. Fludarabine phosphate therapy in other lymphoid malignancies. Semin Oncol 17 (1990) 66-70
10. Montillo M., Tedeschi A., O'Brien S., et al. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 97 (2003) 114-120
11. Saven A., Emanuele S., Kosty M., Koziol J., Ellison D., and Piro L. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blood 86 (1995) 1710-1716
12. Dearden C.E., Matutes E., Cazin B., et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 98 (2001) 1721-1726
13. Pawson R., Dyer M.J., Barge R., et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 15 (1997) 2667-2672
14. Dearden C.E., and Matutes E. Alemtuzumab in T-cell lymphoproliferative disorders. Best Pract Res Clin Haematol 19 (2006) 795-810
15. Perz J., Topaly J., Fruehauf S., Hensel M., and Ho A.D. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 43 (2002) 149-151
16. Garderet L., Bittencourt H., Kaliski A., et al. Treatment of T-prolymphocytic leukemia with nonmyeloablative allogeneic stem cell transplantation. Eur J Haematol 66 (2001) 137-139
17. Collins R.H., Pineiro L.A., Agura E.D., and Fay J.W. Treatment of T prolymphocytic leukemia with allogeneic bone marrow transplantation. Bone Marrow Transplant 21 (1998) 627-628
18. Murase K., Matsunaga T., Sato T., et al. Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement. Int J Clin Oncol 8 (2003) 391-394
19. Kruspe R.C., Ashraf K.K., Foran J.M., Salzman D.E., Reddy V.V., and Vaughan W.P. Successful treatment of T-cell prolymphocytic leukemia with full-intensity conditioning followed by matched unrelated donor allogeneic stem cell transplantation. Clin Adv Hematol Oncol 5 (2007) 882-884 discussion 884
20. Castagna L., Sarina B., Todisco E., Mazza R., and Santoro A. Allogeneic peripheral stem-cell transplantation with reduced-intensity conditioning regimen in refractory primary B-cell prolymphocytic leukemia: a long-term follow-up. Bone Marrow Transplant 35 (2005) 1225